GDC-0575 is primarily investigated for its potential in cancer therapy. It functions as a selective inhibitor of CHK1 (Checkpoint kinase 1), a protein involved in the DNA damage response pathway. By inhibiting CHK1, GDC-0575 disrupts the cell's ability to repair DNA damage, particularly in cancer cells, which are often reliant on this pathway for survival. This makes cancer cells more susceptible to DNA-damaging agents like chemotherapy or radiation. In preclinical studies, GDC-0575 has shown promise in enhancing the efficacy of traditional cancer treatments, especially in tumors with high levels of replication stress or DNA damage. It is being explored in combination therapies to improve outcomes in various cancers, including solid tumors and hematologic malignancies. Research is ongoing to determine its optimal use in clinical settings, focusing on patient populations that may benefit most from this targeted approach.